Brief: Casi Pharmaceuticals Announces Plan To Submit Ind Application For Cid-103, An Anti-Cd 38 Antibody In Antibody-Mediated Rejection, And Receipt Of A Non-Binding Proposal To Acquire Entire China Business Of The Company
26/06/2024 21:18
CASI Pharmaceuticals Inc CASI.O :
* CASI PHARMACEUTICALS ANNOUNCES PLAN TO SUBMIT IND
APPLICATION
FOR CID-103, AN ANTI-CD 38 ANTIBODY IN ANTIBODY-MEDIATED
REJECTION, AND RECEIPT OF A NON-BINDING PROPOSAL TO ACQUIRE
ENTIRE CHINA BUSINESS OF THE COMPANY
* CASI PHARMACEUTICALS INC - TO SUBMIT IND APPLICATION FOR
CID-103
BY END OF 2024
* CASI PHARMACEUTICALS INC - BOARD GOT A PRELIMINARY
NON-BINDING
PROPOSAL LETTER DATED JUNE 21, FROM WEI-WU HE, CHAIRMAN OF BOARD
AND CEO OF COMPANY
* CASI PHARMACEUTICALS INC - PROPOSED DEAL FOR PURCHASE
PRICE OF
$40.0 MILLION, WHICH SHALL INCLUDE ASSUMPTION OF UP TO $20.0
MILLION OF INDEBTEDNESS OF COMPANY
Source text for Eikon: ID:nPn3ZJtvDa
Further company coverage: CASI.O
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary